On April 14, according to the Shenzhen Government Procurement Network, the Shenzhen Center for Disease Control and Prevention announced the results of the city's influenza vaccination project for people aged 60 and above. Hualan Vaccine (full name "Hualan Biological Vaccine Co., Ltd.") won the bid for the trivalent influenza vaccine at 10 yuan per shot.

It is understood that this is also the first influenza vaccine bidding project in the country this year.

In recent years, the winning bid price of public influenza vaccines has declined significantly, and the winning bid price of products has occurred several times at about 10 yuan per shot. Interface News previously reported that in October last year, Beijing Kexing's trivalent influenza vaccine won the bid at a price of 10.5 yuan per shot. At that time, Fosun Yalifeng, which participated in the same bidding, quoted as low as 6.5 yuan per shot. In September last year, the winning bid price of the influenza vaccine of the Shanghai Institute of Biological Products was 9.4 yuan per shot.

However, the influenza vaccine purchased by Shenzhen this time is a pre-injection product, which means that the cost of the vaccine product will be higher than the common vial dosage form.

Influenza vaccine is a landmark product in the vaccine field. Influenza is one of the top five Class C infectious diseases in China, and the huge number of influenza patients has laid a foundation for the widespread demand for influenza vaccines.

According to Moentropy Pharmaceutical Data, as of now, according to the number of winning bids, Hualan Vaccine, Sinovac Biotech, Changchun Institute of Biological Products, Fosun Yalifeng, Sanofi Pasteur, Shanghai Institute of Biological Products, Guoguang Biotech, Jindik, Wuhan Institute of Biological Products, and Tianyuan Biotech are the companies with the largest number of winning bids in China.

From the market supply side, the number of influenza vaccine signings and wholesales is increasing. From 2017 to 2022, data disclosed by the China Food and Drug Inspection Institute showed that the number of influenza virus split vaccine signings and wholesales increased from 24.943 million to 65.621 million, with an annual compound growth rate of 21.3%.

According to data from the National Health Commission, from 2017 to 2022, the number of influenza cases in China increased from 457,000 to 2.443 million, with a compound annual growth rate of 39.8%. From the perspective of disease prevention and control, influenza vaccines should be the most promising products in the vaccine field.

However, the domestic influenza vaccine market has long changed. In the field of influenza vaccines, trivalent vaccines are no longer the mainstream product. According to the wholesale data signed by the China National Institute for Inspection and Quarantine, in 2023, the market share of quadrivalent influenza vaccines has risen to 75%, which is higher than trivalent vaccines in terms of proportion.

In the category of quadrivalent vaccines, since May 2024, Sinopharm Group has taken the lead in reducing the price of quadrivalent influenza split vaccines, bringing the unit price of the product within 100 yuan. In the same month, Jiangsu Province was the first to issue a notice to adjust the supply prices of some vaccines. Among them, the online price of pre-filled quadrivalent influenza split vaccines of Changchun Biological Products, Wuhan Biological Products, and Shanghai Biological Products has dropped from 128 yuan to 88 yuan.

Later, in Guangdong, Shanghai, Guangxi, Jilin, Tianjin, Heilongjiang, Fujian, Jiangxi, Hunan, Hubei and other provinces and cities, the pre-filled quadrivalent influenza split vaccine listed by Sinopharm Group was reduced to 88 yuan. From the perspective of corporate dynamics, after Sinopharm Group, Hualan Vaccine, Sinovac Biotech, Jindik and others also cut prices, jointly pulling the price of quadrivalent influenza vaccine down by 100 yuan.

After falling into a vaccine price war, the performance of Hualan Vaccine, a listed company, has declined significantly. In 2024, the company's revenue and net profit attributable to shareholders were 1.128 billion yuan and 206 million yuan, respectively, down 53.21% and 76.1% from the same period last year. Hualan Vaccine was established in 2005 and is currently the leading influenza virus split vaccine producer and distributor in China.

https://finance.eastmoney.com/a/202504153377602190.html